The Lancet says Russian Sputnik V vaccine passed late stage trials, gives 92% protection and is considered ‘safe’

0
38
Enterprise News and Pictures 2/2/21 Pic shows: Russia's Sputnik V coronavirus vaccine, which gives around 92% protection against Covid-19, The Lancet has just revealed the late stage trial results and their published findings also deem the Russian vaccine safe to administer. It also provides total protection against hospitalisation and death. The results would appear to allay the initial fear that the vaccine was being released into production before final trial data had been fully scrutinised. Sputnik V uses a common cold-form of a virus created to be harmless as the carrier which introduces a tiny amount of the coronovirus into the body. That way the body is safely exposed to the genetic code of the virus, so it sees the approaching threat and learns how to fight it, avoiding the risk of the recipient suffering it's ill-effects. Following vaccination the system begins to produce antibodies specifically aimed at the coronavirus. This ensures the immune system is ready to combat Covid-19 if it encounters the real thing. The Sputnik vaccine, although similar to the UK developed Oxford/AstraZeneca jab and the Janssen vaccine developed in Belgium, is different in that is uses two slightly varied versions of the vaccine for the initial and second dose. The doses are spread 21 days apart but the different formulas are said to give a greater boost to the immune system because of the variation. The Lancet said results showed it was safe with no serious side effects during the trial with no serious illness or deaths in those vaccinated. There were some mild side effects similar to those in the other vaccines, such as tiredness, a slight temperature and a sore arm. The Sputnik V vaccine is shown here in photos distributed for general use by the Russian Ministry of Health. See story...

Russia’s Sputnik V coronavirus vaccine gives around 92% protection against Covid-19 and is considered safe, The Lancet reports.

The weekly medical journal has just revealed the late stage trial results and their published findings deem the Russian vaccine safe to administer. It also provides total protection against hospitalisation and death.

The results would appear to allay the initial fear that the vaccine was being released into production before final trial data had been fully scrutinised.

Sputnik V uses a common cold-form of a virus created to be harmless as the carrier which introduces a tiny amount of the coronavirus into the body. That way the body is safely exposed to the genetic code of the virus, so it sees the approaching threat and learns how to fight it, avoiding the risk of the recipient suffering it’s ill-effects.

Russian Ministry of Health
Following vaccination the system begins to produce antibodies specifically aimed at the coronavirus. This ensures the immune system is ready to combat Covid-19 if it encounters the real thing.

The Sputnik vaccine, although similar to the UK developed Oxford/AstraZeneca jab and the Janssen vaccine developed in Belgium, is different in that it uses two slightly varied versions of the vaccine for the initial and second dose.

The doses are spread 21 days apart but the different formulas are said to give a greater boost to the immune system because of the variation.

Sputnik V is administered 

The Lancet said results showed it was safe with no serious side effects during the trial with no serious illness or deaths in those vaccinated. There were some mild side effects similar to those in the other vaccines, such as tiredness, a slight temperature and a sore arm.
Follow us on Faceboook, Instagram, Twitter and Linkedin #globalnetpictures #GlobalNet_Pics #SputnikV #Covid19 #coronavirus #TheLancet #covidvaccine #Russianvaccine #vaccine

LEAVE A REPLY

Please enter your comment!
Please enter your name here